Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Open accessThe DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
Abstract
The Clinical Practice Manual for Hepatocellular Carcinoma was published based on evidence confirmed by the Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma along with consensus opinion among a Japan Society of Hepatology (JSH) expert panel on hepatocellular carcinoma (HCC). Since the JSH Clinical Practice Guidelines are based on original articles with extremely high levels of evidence, expert opinions on HCC management in clinical practice or consensus on newly developed treatments are not included. However, the practice manual incorporates the literature based on clinical data, expert opinion, and real-world clinical practice currently conducted in Japan to facilitate its use by clinicians. Alongside each revision of the JSH Guidelines, we issued an update to the manual, with the first edition of the manual published in 2007, the second edition in 2010, the third edition in 2015, and the fourth edition in 2020, which includes the 2017 edition of the JSH Guideline. This article is an excerpt from the fourth edition of the HCC Clinical Practice Manual focusing on pathology, diagnosis, and treatment of HCC. It is designed as a practical manual different from the latest version of the JSH Clinical Practice Guidelines. This practice manual was written by an expert panel from the JSH, with emphasis on the consensus statements and recommendations for the management of HCC proposed by the JSH expert panel. In this article, we included newly developed clinical practices that are relatively common among Japanese experts in this field, although all of their statements are not associated with a high level of evidence, but these practices are likely to be incorporated into guidelines in the future. To write this article, coauthors from different institutions drafted the content and then critically reviewed each other’s work. The revised content was then critically reviewed by the Board of Directors and the Planning and Public Relations Committee of JSH before publication to confirm the consensus statements and recommendations. The consensus statements and recommendations presented in this report represent measures actually being conducted at the highest-level HCC treatment centers in Japan. We hope this article provides insight into the actual situation of HCC practice in Japan, thereby affecting the global practice pattern in the management of HCC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In general, European and US guidelines recommend more-restrictive criteria for resection than Asian guidelines7,22–27.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [23]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,700
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Forner, A., Reig, M., & Bruix, J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30010-2 · Cited by 5,531
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Cited by
Items 301–400 of 678
Watanabe, Y., Aikawa, M., Murase, Y., Takase, K., Watanabe, Y., Ono, H., Okada, K., Okamoto, K., & Koyama, I. (2025) · Hepatology International · doi:10.1007/s12072-025-10879-3 · Cited by 8
“Treatment strategies for HCC followed the Japan Society of Hepatology algorithm [16].”
Takaya, H., Namisaki, T., Matsumoto, K., Suzuki, J., Murata, K., Tsuji, Y., Nakanishi, K., Kaji, K., Kitade, M., Noguchi, R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020434 · Cited by 6
Teranishi, R., Takahashi, T., Nishida, T., Hirota, S., Kurokawa, Y., Saito, T., Yamamoto, K., Yamashita, K., Tanaka, K., Makino, T., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02159-z · Cited by 7
“Currently, REG is approved as a treatment option for patients with advanced stage colorectal cancer (CRC), hepatocellular carcinoma (HCC), and GIST in Japan [24, 25].”
BackgroundRattananukrom, C., & Kitiyakara, T. (2022) · JGH Open · doi:10.1002/jgh3.12753 · Cited by 6
Ueda, S., Hori, S., Hori, A., Makitani, K., Wan, K., & Sonomura, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s380439 · Cited by 6
Wong, J. K., Lim, H. J., Tam, V. C., Burak, K. W., Dawson, L. A., Chaudhury, P. K., Abraham, R. J., Meyers, B. M., Sapisochín, G., Valenti, D. A., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102526 · Cited by 7
Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16225 · Cited by 7
Self-citationZhou, P., Liu, Y., Wu, G., Lu, K., Zhao, T., & Yang, L. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2023.2216966 · Cited by 6
“Hepatocellular carcinoma (HCC) is a prevalent primary malignant disease which occupies the considerable proportion in cancer-related death in most of the countries (D. P. Wang et al., 2020; Kudo et al., 2021).”
Kim, S. H., Kim, J. H., Kim, G. H., Kim, J. H., Ko, H.-K., Chu, H. H., Shin, J. H., Gwon, D. I., Ko, G., Yoon, H.-K., et al. (2023) · European Radiology · doi:10.1007/s00330-023-09961-x · Cited by 6
“Furthermore, improvements in chemoembolization devices and techniques have increased patient survival while decreasing chemoembolization-associated mortality [15, 16].”
BackgroundGuo, Y., Wu, J., Liang, L., Zhu, K., Zhou, J., Lin, L., Chen, Y., Cao, B., Mingji, H., Lian, H., et al. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00604-4 · Cited by 6
Yi, J., Zhu, Z., Liu, G., Zhang, Y., Xu, J., Wu, X., Ding, K., Liu, J., Zhang, K., Jiang, X., et al. (2023) · Hepatology Research · doi:10.1111/hepr.14007 · Cited by 7
“24 According to the Korean practice guidelines for HCC management, HAIC is also recommended for patients with advanced HCC who have failed or are unsuitable for systemic therapies.”
Peng, G., Cao, X., Huang, X., & Zhou, X. (2024) · European Journal of Radiology Open · doi:10.1016/j.ejro.2024.100551 · Cited by 7
“Treatment was discontinued in cases of TACE refractoriness [17], severe complications, or withdrawal of consent.”
BackgroundRonot, M. (2022) · Radiology · doi:10.1148/radiol.213224 · Cited by 6
Kudo, M., Ikeda, M., Aikata, H., Numata, K., Marusawa, H., Hosaka, T., Kato, N., Kurosaki, M., Morimoto, M., Yamashita, T., et al. (2024) · Liver Cancer · doi:10.1159/000542572 · Cited by 9
Self-citationZhang, C., Xu, Y., Cai, L., Zhou, S., Feng, J., Fu, S., Wang, W., Liang, W., Li, C., Guo, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-08170-4 · Cited by 5
“By following the guidelines to minimize variations in interventional procedures across centers, multi – center data can better represent real – world universality 18,19 .”
Liu, B., Yin, L., Chen, Y., Hou, X., Li, Y., Liu, X., & Liu, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1615506 · Cited by 5
Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma
Jiang, J., Cao, Y., Gao, S., Hu, Y., Yang, S., & Tang, H. (2025) · iLiver · doi:10.1016/j.iliver.2025.100187 · Cited by 6
“73 Strategies such as lenvatinib pretreatment followed by selective TACE have shown potential benefit in this population.”
InfluentialMaesaka, K., Hikita, H., Tahata, Y., Nishioka, C., Kai, M., Shirai, K., Murai, K., Makino, Y., Saito, Y., Kodama, T., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02308-x · Cited by 4
Self-citationBártulos, C. R., Senk, K., Bade, R., Schumacher, M., Kaiser, N., Plath, J., Planert, M., Stroszczynski, C., Woetzel, J., & Wiggermann, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-39954-1 · Cited by 7
“Both of these clinical guidelines have incorporated the ALBI scoring system as an important component in their latest version 29–31 .”
BackgroundLi, H., Kang, W., & Rong, P. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-963 · Cited by 6
“The concept of TACE-refractory/failed was first introduced by the Japanese Society of Hepatology (JSH) and revised in 2014 and 2021 (4,5).”
A tumor endothelial cell-specific microRNA replacement therapy for hepatocellular carcinoma
Iwamoto, H., Suzuki, H., Masuda, A., Sakaue, T., Nakamura, T., Tanaka, T., Sakai, M., Imamura, Y., Yano, H., Torimura, T., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108797 · Cited by 5
Self-citationPhysical activity and exercise in liver cancer
Chen, H., Zhou, H., Wu, B., Lu, H., Zhang, J., Zhang, Y., Gu, Y., Guangwen, Z., Xiang, J., & Yang, J. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.001 · Cited by 5
Hatanaka, T., Kakizaki, S., Hiraoka, A., Tada, T., Kariyama, K., Itobayashi, E., Tsuji, K., Ishikawa, T., Toyoda, H., Koshiyama, Y., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17025 · Cited by 5
Self-citationHan, X., Long, W., Liu, Y., & Xu, J. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.985034 · Cited by 6
“The treatment of HCC mainly includes surgical resection, liver transplantation, vascular intervention and radiofrequency ablation (5).”
Fuji, T., Arai, J., Otoyama, Y., Nio, Y., Sugiura, I., Nakajima, Y., Kajiwara, A., Ichikawa, Y., Uozumi, S., Shimozuma, Y., et al. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s383769 · Cited by 5
“implicated in angiogenic and tumor.(5,7) Recent evidence has shown that its antitumor efficacy is due to a comprehensive spectrum of tumor neo-angiogenesis, enhancement of immunosurveillance by natural killer cells, and immunomodulatory effects on the tumor microenvironment, which plays a crucial role in tumor develop…”
BackgroundAntitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
Oura, K., Morishita, A., Tani, J., & Masaki, T. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s392051 · Cited by 6
“Systemic therapy of advanced HCC that is unresectable due to major vascular invasion and/or metastasis generally involves immune checkpoint inhibitors and molecular targeted agents with several currently available drugs including atezolizumab/bevacizumab combination therapy for first-line therapy and sorafenib, lenvat…”
BackgroundWang, K., Yu, H., Xiang, Y., Cheng, Y., Ni, Q., Guo, W., Shi, J., Feng, S., Zhai, J., & Cheng, S. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064688 · Cited by 5
Cox, D. R. A., Chung, W., Grace, J., Wong, D. J., Kutaiba, N., Ranatunga, D. G., Khor, R., Perini, M. V., Fink, M. A., Jones, R. M., et al. (2023) · JGH Open · doi:10.1002/jgh3.12879 · Cited by 5
Hou, S., Hua, S., Cui, K., Liu, F., Ding, K., & Yuan, J. (2023) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-22-292 · Cited by 5
Pan, Y., Yang, L., Cao, Y., Jun, H., Tang, H., Zhang, W., Wan, T., Jiao, T., Hu, B., & Lu, S. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-70 · Cited by 5
Chen, C., Liu, J., Gu, Z., Sun, Y.-J., Lu, W., Liu, X., Chen, K., Ma, T., Zhao, S., & Zhao, H. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s423129 · Cited by 6
“The Japanese Society of Hepatology (JSH)-liver cancer research group (LCSGJ) considered that TACE resistance could be judged by the presence of more than 50% residual activity or new lesions on CT/MRI 1–3 months after two or more consecutive TACE treatments.(40) If tumor progression occurs after TACE, TACE treatment c…”
BackgroundXiong, J., Zhou, Y., Tan, K., Liu, H., Cao, Y., Liu, J., Wu, W., Du, X., & Luo, Z.-H. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-523 · Cited by 5
Liu, C., Xiao, Z., Wu, S., Yang, Z., Ji, G., Duan, J., Zhou, T., Cao, J., Liu, X., & Xu, F. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107694 · Cited by 5
Brandi, N., & Renzulli, M. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00130 · Cited by 5
Changez, M. I. K., Khan, M., Uzair, M., Tahir, M. F., Mohsin, M., Hussain, A. F., Saqib, V., Molani, M. K., Ahmed, A. H., & Khalid, S. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00999-0 · Cited by 6
“Hence, favoring atezolizumab and bevacizumab, a finding further consolidated by the phase III trials, with ORR findings of 30% for atezolizumab and bevacizumab and 24.1% for lenvatinib [24, 25].”
InfluentialSurgical resection for hepatocellular carcinoma: a single-centre’s one decade of experience
Syaiful, R. A., Mazni, Y., Siagian, N. K. P., Putranto, A. S., Jeo, W. S., Rahadiani, N., Ibrahim, F., Sihardo, L., Marbun, V. M. G., Lalisang, A. N. L., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001746 · Cited by 5
“Liver resection is one of the HCC treatment modalities, along with liver transplant, radiofrequency ablation (RFA), transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), and systemic therapy [5] .”
BackgroundLiu, Q., Zhang, Y., Zhang, J., Chen, L., Yang, Y., & Liu, Y. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1374149 · Cited by 5
Hu, Z., Yang, Z., Fu, Z., Fu, Y., Ma, Z., Zhou, Z., Chen, M., & Zhang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1472870 · Cited by 7
Tsuzaki, J., Ueno, A., Masugi, Y., Tamura, M., Yamazaki, S., Matsuda, K., Kurebayashi, Y., Sakai, H., Yokoyama, Y., Yuta, A., et al. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae187 · Cited by 6
“…standard in the clinical setting to proceed with diagnosis and treatment without obtaining histological findings, provided these typical findings, such as hyper-enhancement in the arterial phase and washout in the delayed phase, have been obtained in dynamic contrast-enhanced examinations [3].”
Self-citationMatono, T., Tada, T., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14224 · Cited by 7
“Various clinical parameters, including age, sex, tumor marker levels, liver function, degree of liver fibrosis, and HCC stage, have been identified as predictors of survival in patients undergoing HCC treatment [1, 12–14].”
Self-citationLu, H.-Z., Mai, R., Wang, X.-B., Chen, J., Bai, T., Ma, L., Xiang, B., Cheng, S., Guo, W., Li, L., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1297 · Cited by 5
Omiya, S., Komatsu, S., Terashima, K., Yamasaki, N., Matsuo, Y., Toyama, H., Tokumaru, S., Okimoto, T., & Fukumoto, T. (2022) · Journal of the American College of Surgeons · doi:10.1097/xcs.0000000000000532 · Cited by 5
Cho, S. H., You, G. R., Park, C., Cho, S., Lee, J. E., Choi, S. K., Cho, S. B., & Yoon, J. H. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i5.892 · Cited by 5
Zhang, L., Zheng, T., Wu, Y., Wei, H., Yang, T., Zhu, X., Yang, J., Chen, Y., Wang, Y., Qu, Y., et al. (2023) · European Journal of Radiology · doi:10.1016/j.ejrad.2023.110895 · Cited by 5
Pan, C., Dai, F., Sheng, L., Li, K., Qiao, W., Kang, Z., & Zhang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1348679 · Cited by 5
Kinami, T., Uchikawa, S., Kawaoka, T., Yamasaki, S., Kosaka, M., Johira, Y., Yano, S., Amioka, K., Naruto, K., Yamaoka, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7025 · Cited by 5
“10 Because it was confirmed that Atezo + Beva maintained patients' quality of life and prolonged survival better than sorafenib in the IMbrave150 trial, 11 Atezo + Beva was used as a first-line treatment.”
MethodFactors for the recurrence of hepatocellular carcinoma after hepatic resection
Tsuge, M., Kawaoka, T., & Oka, S. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-01962-3 · Cited by 5
Kobayashi, K., Ogasawara, S., Itobayashi, E., Okubo, T., Itokawa, N., Nakamura, K., Moriguchi, M., Watanabe, S., Ikeda, M., Kuroda, H., et al. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01441-3 · Cited by 8
“Despite global guidelines advocating early detection through surveillance of high-risk groups, many patients are still diagnosed at advanced stages [5–8].”
BackgroundSelf-citationNakabori, T., Higashi, S., Mukai, K., Ikawa, T., Maeda, N., Kawabata, M., Hosokawa, K., Kozumi, K., Urabe, M., Kai, Y., et al. (2025) · Oncology · doi:10.1159/000546211 · Cited by 5
“…immunotherapy, including atezolizumab plus bevacizumab (atezo/bev) [4] and durvalumab and tremelimumab [5], has demonstrated superior outcomes for patients with unresectable HCC compared to sorafenib, leading to their global approval as fi rst-line systemic therapies for unresectable HCC [6 – 9].”
Ueshima, K., Tsuchiya, K., Yamashita, T., Shimose, S., Numata, K., Kodama, Y., Itoh, S., Tanaka, Y., Kuroda, H., Ohkawa, K., et al. (2025) · Liver International · doi:10.1111/liv.70379 · Cited by 6
Self-citationLi, H., Fan, Y., Li, Y., & Ren, W. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05285-0 · Cited by 4
“According to the revised TACE resistance criteria by JSH-LCSGJ in 2021 [ 19 ], treatment resistance is not considered a termination indicator.”
Early screening for liver cancer must be performed
Liu, Z., Wang, W., & Dang, S. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i11.112675 · Cited by 5
Mizumoto, M., Shibuya, K., Terashima, K., Iwata, H., Saito, T., Toyama, S., Ogino, T., Murakami, M., OHNO, T., Sato, Y., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71639 · Cited by 4
Self-citationLiu, Q., Liu, T., Liu, X., Zhang, F., Yang, J., Cheng, Y., & Yang, Q. (2024) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-23-1184 · Cited by 4
Peng, G., Huang, X., Wang, Y., Cao, X., & Zhou, X. (2024) · Radiology Imaging Cancer · doi:10.1148/rycan.230167 · Cited by 4
Inoue, M., Ogasawara, S., Kobayashi, K., Okubo, T., Itokawa, N., Obu, M., Fujimoto, K., Unozawa, H., Yumita, S., Fujiwara, K., et al. (2024) · Liver Cancer · doi:10.1159/000539380 · Cited by 7
Self-citationSurvival benefit of sequential curative treatment for TACE suitable BCLC stage B HCC patients
Ding, Y., Chang, T., Shen, C., Kuo, L.-M., Hsu, S.-L., Chen, Y., Hsieh, Y., Huang, H.-L., & Lu, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-72767-4 · Cited by 4
Amano, K., Sano, T., Ide, T., Nakano, D., Tsutsumi, T., Arinaga‐Hino, T., Kawaguchi, M., Hirai, S., Miyajima, I., Torimura, T., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.3867-24 · Cited by 6
“The diagnosis of HCC was based on the criteria of the clinical practice manual proposed by JSH using serum AFP and DCP levels and imaging techniques, including ultra-sonography, computed tomography, magnetic resonance imaging, hepatic angiography, and/or a tumor biopsy (16).”
Zhou, Y. B., Li, J., Li, Q., Liu, L., Huang, P., Mao, Y., Yang, Y., Lv, F., & Liu, Z. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s527789 · Cited by 5
“Although mRECIST is currently used as the most commonly used imaging tumor response assessment after HCC conversion therapy, 10,14,15,18,24,25 it is not an independent predictor of RFS and only showed statistically different in the univariable Cox regression analyses ( p = 0.024).”
InfluentialPark, M.-S., Cho, J. Y., Kim, E., Na, H. Y., Choi, Y., Kim, N. R., Yoon, Y., Lee, B., Jang, E. S., Jung, Y. K., et al. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.08.05 · Cited by 4
Kim, T. H., Kim, B. H., Cho, Y., Koh, Y. H., & Park, J. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.04.14 · Cited by 4
Hien, P. N., Chun, H. J., Oh, J. S., Kim, S. H., & Choi, B. G. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-1006 · Cited by 4
Du, C., Wu, H., Zhong, T., Zhai, Q., Yuan, J., Peng, J., Ma, R., & Li, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01026-9 · Cited by 4
Wang, F., Numata, K., Funaoka, A., Liu, X., Kumamoto, T., Takeda, K., Chuma, M., Nozaki, A., Ruan, L., & Maeda, S. (2024) · BioScience Trends · doi:10.5582/bst.2024.01112 · Cited by 4
Ma, Y., Jiang, X., Hu, X., Wang, L., Gao, J., Liu, H., Qi, F., Song, P., & Tang, W. (2024) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-024-4111-z · Cited by 4
Yamauchi, M., Maekawa, M., Sato, T., Sato, Y., Kumondai, M., Tsuruoka, M., Inoue, J., Masamune, A., & Mano, N. (2024) · Metabolites · doi:10.3390/metabo14090513 · Cited by 6
“HCC is mainly diagnosed using imaging modalities, such as computed tomography and magnetic resonance imaging, when nodular lesions are detected by abdominal ultrasound [5–8].”
Asano, K., Kageyama, K., Yamamoto, A., Jogo, A., Nakano, M., Murai, K., Yukawa‐Muto, Y., Odagiri, N., Kotani, K., Kozuka, R., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70367 · Cited by 4
“Lesions that are prone to cause deterioration of liver function in Child-Pugh class B have been reported to be unsuitable for TACE [3].”
BackgroundMethodInfluentialHiraoka, A., Kudo, M., Tada, T., Hatanaka, T., Kakizaki, S., Kariyama, K., Ohama, H., Tsuji, K., Ishikawa, T., Takaguchi, K., et al. (2025) · Oncology · doi:10.1159/000543405 · Cited by 5
“Combined use of tumor markers for enhancing detection of HCC with use of ultrasonography has been reported [37].”
Self-citationHong, X., Guo, Y., Shi, W., Zhu, K., Liang, L., Lin, L., Chen, Y., Zhou, J., Huang, J., Huang, J., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13605-2 · Cited by 5
Hou, Y., Zhang, T.-Q., Ma, L., Jiang, Y., Han, X., Di, T., Tang, L., Guo, R., Chen, M. S., Zhang, J., et al. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.02.012 · Cited by 5
Peng, N., Mao, L., Su, J., Liu, S., Ou, J., Chen, S., Su, Z., Li, W., Yang, F., Zhou, Y.-H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593153 · Cited by 6
Chen, S., Yu, W., Zhang, K., Liu, W., Wang, X., & Chen, C. (2022) · Gastroenterology report · doi:10.1093/gastro/goac016 · Cited by 4
Ge, C., Luo, M., Guo, K., Zhu, D., Han, N., Wang, T., & Zhao, X. (2022) · iLiver · doi:10.1016/j.iliver.2022.11.003 · Cited by 4
“Recently, several other serum markers have been reported for HCC diagnosis and prognosis; among them, protein induced by vitamin K absence or antagonist II (PIVKA-II) has been reported to be combined with AFP to improve the HCC diagnostic performance by the Japan Society of Hepatology [7].”
Chen, J., Lai, L., Luo, J., Wang, H., Li, M., & Huang, M. (2022) · BMC Cancer · doi:10.1186/s12885-022-10361-5 · Cited by 4
“We assumed that there might be two reasons: first,patients with severe APS (classification 1–3: 11 patients in DEM-TACE group and 14 patients in C-TACE group) might be not suitable for TACE procedure, even when using the HepaSphere microspheres, which might pass through the shunt during TACE[35].”
BackgroundTajiri, K., Tokimitsu, Y., Kawai, K., Motofuji, Y., Shinno, E., Kashii, Y., Muraishi, N., Murayama, A., Hayashi, Y., Minemura, M., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.16112 · Cited by 5
“However, patients with TACE-refractory (27) or TACE-unsuitable (28) were considered for lenvatinib administration.”
BackgroundHu, Z., Yang, Z., Pan, Y., Fu, Y., Wang, J., Zhou, Z., Chen, M., Hu, D., & Zhang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1210835 · Cited by 4
Huang, P., Shi, Q., Ni, X., Liu, L., Zhou, C., Wu, F., Wang, C., Xiao, Y., Miao, G., Yang, C., et al. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-04024-7 · Cited by 4
Tajiri, K., Tsukada, K., Tokimitsu, Y., Motofuji, Y., Kawai, K., Muraishi, N., Murayama, A., Hayashi, Y., Shimizu, Y., & Yasuda, I. (2023) · Oncology · doi:10.1159/000533952 · Cited by 6
“HCC treatment was determined by discussions among hepatologists, surgeons, and radiologists at each institution according to Japanese practice guidelines for HCC [13].”
MethodKariyama, K., Nouso, K., Hiraoka, A., Toyoda, H., Tada, T., Tsuji, K., Ishikawa, T., Hatanaka, T., Itobayashi, E., Takaguchi, K., et al. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.09.11 · Cited by 4
“Recently, there has been a heated debate over the choice between surgery and ablation for a solitary HCC measuring > 3 cm but < 5 cm. 8,12,16,17 Ng et al. 8 demonstrated that ablation is not significantly different from surgery in terms of OS and RFS for single HCCs measuring ≤ cm in diameter.”
BackgroundSelf-citationNakamura, S., Tada, T., Sue, M., Matsuo, Y., Murakami, S., Muramatsu, T., Morii, K., & Okada, H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247577 · Cited by 3
“Local tumor recurrence was defined as tumor growth that touched the inside or outside of the post-ablation zone.”
BackgroundMethodInfluentialQin, Z., Zhou, Y., Zhang, X., Ding, J., Zhou, H., Wang, Y., Zhao, L., Chen, C., & Jing, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1345981 · Cited by 4
“This diagnostic criterion was easy to use in clinical work, and this criterion is also consistent with the addition of another imaging examination when there is one imaging uncertainty of HCC diagnosis in the guidelines (25, 26).”
MethodSoghin clinical practice guidelines for hepatocellular carcinoma
Ndububa, D. A., Abdulkareem, F. B., Mustapha, S., Ekwunife, C. N., & Omuemu, C. E. (2023) · Nigerian Journal of Gastroenterology and Hepatology · doi:10.4103/njgh.njgh_6_23 · Cited by 4
Asahi, Y., Kakisaka, T., Kamiyama, T., Orimo, T., Shimada, S., Nagatsu, A., Aiyama, T., Sakamoto, Y., Wakizaka, K., Shichi, S., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14098 · Cited by 4
“3 7 However, recommendations regarding LR for more advanced HCC differ according to the specific guidelines or staging systems adopted.”
Iwamoto, H., Niizeki, T., Nagamatsu, H., Ueshima, K., Tani, J., Kuzuya, T., Kasai, K., Kooka, Y., Hiraoka, A., Sugimoto, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1811231/v1 · Cited by 4
Self-citationKudo, M., Hiraoka, A., Numata, K., Yamashita, T., Kurosaki, M., Namisaki, T., Hige, S., Itoh, Y., Mochida, S., Hosaka, T., et al. (2025) · Liver Cancer · doi:10.1159/000548300 · Cited by 5
Self-citationLiu, J., Zhang, S., & Shao, H. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099510 · Cited by 5
Park, M.-S., Cho, J. Y., Kim, E., Na, H. Y., Choi, Y., Kim, N. R., Yoon, Y., Lee, B., Jang, E. S., Jung, Y. K., et al. (2025) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2025.109.3.123 · Cited by 3
Le, T. M., & Pham, K. C. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002257 · Cited by 5
Li, Y., Wang, D., Zhang, F., Zheng, X., Song, Y., Ran, Y., & Cai, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638173 · Cited by 4
Meng, X., Chen, F., Tang, T., Xia, T., Qian, Y., Zhao, B., Qu, X., Zhou, Y., Shi, Y., Long, X., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101565 · Cited by 4
“Based on these findings, over 30% of the study population who underwent non-AR might have experienced a reduced risk of early recurrence and improved RFS if AR had been performed, thereby supporting the importance of personalized selection of the optimal hepatectomy type in patients with HCC.”
Peng, Z., Wang, Y., Chen, B., Zhu, Z., He, C., Wei, Y., & Huang, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665348 · Cited by 3
“The value of HAIC in the management of HCC, particularly in advanced cases and those with portal vein tumor thrombosis (PVTT), is well-documented.”
InfluentialKim, J. H., Kim, H. S., Yoon, J. H., Joo, I., Yoon, J., Kim, Y. J., Yu, S. J., & Lee, J. M. (2023) · Cancer Imaging · doi:10.1186/s40644-023-00597-0 · Cited by 3
Watanabe, Y., Aikawa, M., Oshima, Y., Kato, T., Takase, K., Watanabe, Y., Okada, K., Okamoto, K., & Koyama, I. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-10937-1 · Cited by 5
“The therapeutic strategy for HCC was determined using the treatment algorithm of the Japan Society of Hepatology [19].”
Zhang, Y., Wu, X., Yi, J., Xu, J., Zhang, Y.-N., Lyu, N., & Zhao, M. D. (2025) · Liver Cancer · doi:10.1159/000545891 · Cited by 5
“Hepatic arterial infusion chemotherapy (HAIC) is a locoregional treatment widely used in Asia and has been recommended as an alternative fi rst-line treat-ment option for liver-con fi ned HCC and major PVTT [14 – 17].”
Proton beam therapy in the management of hepatocellular carcinoma
Chok, K., Joeng, T. Y., & Poon, D. M. C. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2495080 · Cited by 3
Ngo, M., Dao, T., Hoang, T., Nguyen, U., Stenman, J. J. E., Duong, H., & Ho, T. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-99302-3 · Cited by 3
“Currently, biomarkers like AFP and PIVKA II are utilized predominantly in clinical practice for primary HCC diagnosis 13,14 .”
Maesaka, K., Hikita, H., Kai, M., Tahata, Y., Shirai, K., Doi, A., Murai, K., Saito, Y., Yamada, R., Kodama, T., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70068 · Cited by 3
Self-citationYang, D., Yang, S., Zhao, F., Hu, Y., Zhao, K., Xiong, X., Zhu, M., Pei, J., & Ding, Y. (2022) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2022.2150610 · Cited by 3
Hatanaka, T., Yata, Y., Saito, N., Nakano, S., Nakano, Y., Hazama, Y., Yoshida, S., Hachisu, Y., Tanaka, Y., Yoshinaga, T., et al. (2023) · Cancers · doi:10.3390/cancers15041289 · Cited by 3
“According to the Barcelona Clinic Liver Cancer staging system [2] and the Japan Society of Hepatology guidelines [3], ablation therapy is indicated for Child–Pugh class A or B patients with a tumor size ≤3 cm in diameter and ≤3 nodules.”
MethodHien, P. N., Chun, H. J., Oh, J. S., Kim, S. H., & Choi, B. G. (2023) · Diagnostic and Interventional Radiology · doi:10.4274/dir.2023.232311 · Cited by 3
Metadata
- Authors
- Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., Izumi, N., Moriguchi, M., Ogasawara, S., Minami, Y., Ueshima, K., Murakami, T., Miyayama, S., Nakashima, O., Yano, H., Sakamoto, M., Hatano, E., Shimada, M., Kokudo, N., Mochida, S., Takehara, T., & HCC Expert Panel of the Japan Society of Hepatology
- Affiliations
- Kindai University Hospital (JP)
- Toranomon Hospital (JP)
- The University of Tokyo (JP)
- Okayama City Hospital (JP)
- Juntendo University (JP)
- Ogaki Municipal Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- National Cancer Center Hospital East (JP)
- Musashino Red Cross Hospital (JP)
- Kyoto Prefectural University of Medicine (JP)
- Chiba University (JP)
- Kobe University (JP)
- Fukui-ken Saiseikai Hospital (JP)
- Kurume University (JP)
- Keio University (JP)
- Hyogo Medical University (JP)
- Tokushima University (JP)
- National Center for Global Health and Medicine (JP)
- Saitama Medical University (JP)
- The University of Osaka (JP)
- ORCID
- Kudo, Masatoshi
- Kawamura, Yusuke
- Hasegawa, Kiyoshi
- Tateishi, Ryosuke
- Kariyama, Kazuya
- Shiina, Shuichiro
- Toyoda, Hidenori
- Hiraoka, Atsushi
- Ikeda, Masafumi
- Izumi, Namiki
- Moriguchi, Michihisa
- Ogasawara, Sadahisa
- Minami, Yasunori
- Ueshima, Kazuomi
- Murakami, Takamichi
- Miyayama, Shiro
- Nakashima, Osamu
- Yano, Hirohisa
- Sakamoto, Michiie
- Hatano, Etsuro
- Shimada, Mitsuo
- Kokudo, Norihiro
- Mochida, Satoshi
- Takehara, Tetsuo
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 10
- Issue
- 3
- Pages
- 181-223
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC8237791
- OpenAlex
- W3162270595
- Cited by
- 678
- References
- 200
- Citations by year
- 2026: 78 · 2025: 137 · 2024: 158 · 2023: 177 · 2022: 108 · 2021: 17
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc)
- Funders
- Japan Society for the Promotion of Science (19K08199)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, consensus statement, clinical guidelines, HCC diagnosis, HCC treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.